Abstract
Pegfilgrastim is a sustained-duration form of filgrastim, a recombinant methionyl form of human granulocyte colony-stimulating factor (G-CSF), to which a 20 kDa polyethylene glycol molecule is covalently bound to the N-terminal methionine residue. Similar to filgrastim, pegfilgrastim increases the proliferation and differentiation of neutrophils from committed progenitor cells, induces maturation, and enhances the survival and function of mature neutrophils, resulting in dose-dependent increases in neutrophils.
After subcutaneous administration, pegfilgrastim exhibits nonlinear pharmacokinetics and exposure to pegfilgrastim increases in more than a dose-proportional manner, suggesting that the clearance of pegfilgrastim decreases with increased dosing. Filgrastim is primarily eliminated by the kidney and neutrophils/neutrophil precursors; the latter presumably involves binding of the growth factor to the G-CSF receptor on the cell surface, internalization of the growth factor-receptor complexes via endocytosis, and subsequent degradation inside the cells. Pegylation of filgrastim renders renal clearance insignificant, which was demonstrated in bilaterally nephrectomized rats and confirmed in subjects with renal impairment. As a result, the neutrophil-mediated clearance is the predominant elimination pathway for pegfilgrastim.
During chemotherapy-induced neutropenia, the clearance of pegfilgrastim is significantly reduced and the concentration of pegfilgrastim is sustained until onset of neutrophil recovery. Pegfilgrastim concentrations are sustained longer in patients with profound neutropenia. Evidence supports the use of a postnadir absolute neutrophil count (ANC) of ≥1 × 109/L as a surrogate marker threshold for the clearance of pegfilgrastim to subtherapeutic levels. After repeated administration of pegfilgrastim, the peak concentrations of pegfilgrastim decrease, likely due to increased neutrophil and neutrophil precursor mass.
A pharmacokinetic-pharmacodynamic model was developed to describe the pharmacokinetic and ANC profiles of pegfilgrastim; the analysis supported that 100 µg/kg was an adequate weight-based dose of pegfilgrastim and predicted that 6 mg would be an optimal fixed dose of pegfilgrastim to simplify treatment. Data from a pivotal study confirmed that a once-per-chemotherapy-cycle injection of pegfilgrastim at 6 mg was as safe and effective as 11 daily injections of filgrastim at 5 µg/kg in reducing neutropenia and its complications in patients with breast cancer receiving four cycles of doxorubicin/docetaxel chemotherapy. Because of the highly efficient regulation of pegfilgrastim clearance via neutrophils and neutrophil precursors, a single fixed dose of pegfilgrastim can be given once per chemotherapy cycle in conjunction with a variety of myelosuppressive chemotherapy regimens.
Similar content being viewed by others
References
Dale D. Current management of chemotherapy-induced neutropenia: the role of colony-stimulating factors. Semin Oncol 2003 Aug; 30 (4 Suppl. 13): 3–9
Demetri GD, Griffin JD. Granulocyte colony-stimulating factor and its receptor. Blood 1991 Dec 1; 78(11): 2791–808
Welte K, Gabrilove J, Bronchud MH, et al. Filgrastim (r-metHuG-CSF): the first 10 years. Blood 1996 Sep 15; 88(6): 1907–29
Neupogen®(filgrastim): US prescribing information. Thousand Oaks (CA): Amgen Inc., 2010 Mar [online]. Available from URL: http://www.neupogen.com/pdf/Neupogen_PI.pdf [Accessed 2011 Jan 19]
Kuwabara T, Kobayashi S, Sugiyama Y. Pharmacokinetics and pharmaco-dynamics of a recombinant human granulocyte colony-stimulating factor. Drug Metab Rev 1996 Nov; 28(4): 625–58
Roskos LK, Cheung E, Vincent M, et al. Pharmacokinetics and pharmaco-dynamics of a recombinant human granulocyte colony-stimulating factor. In: Morstyn G, Dexter M, editors. Filgrastim (r-metHuG-CSF) in clinical practice. 2nd ed. New York: Marcel Dekker, Inc., 1998: 51–71
Metcalf D. Hematopoietic cytokines. Blood 2008 Jan 15; 111(2): 485–91
Bartocci A, Mastrogiannis DS, Migliorati G, et al. Macrophages specifically regulate the concentration of their own growth factor in the circulation. Proc Natl Acad Sci U S A 1987 Sep; 84(17): 6179–83
Bukowski RM, Budd GT, Gibbons JA, et al. Phase I trial of subcutaneous recombinant macrophage colony-stimulating factor: clinical and immuno-modulatory effects. J Clin Oncol 1994 Jan; 12(1): 97–106
Kato M, Kamiyama H, Okazaki A, et al. Mechanism for the nonlinear pharmacokinetics of erythropoietin in rats. J Pharmacol Exp Ther 1997 Nov; 283(2): 520–7
Jelkmann W. The enigma of the metabolic fate of circulating erythropoietin (Epo) in view of the pharmacokinetics of the recombinant drugs rhEpo and NESP. Eur J Haematol 2002 Nov-Dec; 69(5-6): 265–74
Gross AW, Lodish HF. Cellular trafficking and degradation of erythropoietin and novel erythropoiesis stimulating protein (NESP). J Biol Chem 2006 Jan 27; 281(4): 2024–32
Nichol JL. The Mpl ligand and platelet homeostasis. Acta Paediatr Suppl. 1998 Jun; 424: 7–15
Scheding S, Bergmann M, Shimosaka A, et al. Human plasma thrombopoietin levels are regulated by binding to platelet thrombopoietin receptors in vivo. Transfusion 2002 Mar; 42(3): 321–7
Petros WP, Rabinowitz J, Stuart AR, et al. Disposition of recombinant human granulocyte-macrophage colony-stimulating factor in patients receiving high-dose chemotherapy and autologous bone marrow support. Blood 1992 Sep 1; 80(5): 1135–40
Layton JE, Hockman H, Sheridan WP, et al. Evidence for a novel in vivo control mechanism of granulopoiesis: mature cell-related control of a regulatory growth factor. Blood 1989 Sep; 74(4): 1303–7
Stute N, Santana VM, Rodman JH, et al. Pharmacokinetics of subcutaneous recombinant human granulocyte colony-stimulating factor in children. Blood 1992 Jun 1; 79(11): 2849–54
Kearns CM, Wang WC, Stute N, et al. Disposition of recombinant human granulocyte colony-stimulating factor in children with severe chronic neu-tropenia. J Pediatr 1993 Sep; 123(3): 471–9
Takatani H, Soda H, Fukuda M, et al. Levels of recombinant human granulocyte colony-stimulating factor in serum are inversely correlated with circulating neutrophil counts. Antimicrob Agents Chemother 1996 Apr; 40(4): 988–91
Sturgill MG, Huhn RD, Drachtman RA, et al. Pharmacokinetics of intravenous recombinant human granulocyte colony-stimulating factor (rhG-CSF) in children receiving myelosuppressive cancer chemotherapy: clearance increases in relation to absolute neutrophil count with repeated dosing. Am J Hematol 1997 Feb; 54(2): 124–30
Wang YM, Krzyzanski W, Doshi S, et al. Pharmacodynamics-mediated drug disposition (PDMDD) and precursor pool lifespan model for single dose of romiplostim in healthy subjects. AAPS J 2010; 12: 729–40
Panopoulos AD, Watowich SS. Granulocyte colony-stimulating factor: molecular mechanisms of action during steady state and ‘emergency’ hema-topoiesis. Cytokine 2008 Jun; 42(3): 277–88
Kuwabara T, Uchimura T, Kobayashi H, et al. Receptor-mediated clearance of G-CSF derivative nartograstim in bone marrow of rats. Am J Physiol 1995 Jul; 269(1 Pt 1): E1–9
Kuwabara T, Uchimura T, Takai K, et al. Saturable uptake of a recombinant human granulocyte colony-stimulating factor derivative, nartograstim, by the bone marrow and spleen of rats in vivo. J Pharmacol Exp Ther 1995 Jun; 273(3): 1114–22
Kuwabara T, Kobayashi S, Sugiyama Y. Kinetic analysis of receptor-mediated endocytosis of G-CSF derivative, nartograstim, in rat bone marrow cells. Am J Physiol 1996 Jul; 271(1 Pt 1): E73–84
Terashi K, Oka M, Ohdo S, et al. Close association between clearance of recombinant human granulocyte colony-stimulating factor (G-CSF) and G-CSF receptor on neutrophils in cancer patients. Antimicrob Agents Chemother 1999 Jan; 43(1): 21–4
Khwaja A, Carver J, Jones HM, et al. Expression and dynamic modulation of the human granulocyte colony-stimulating factor receptor in immature and differentiated myeloid cells. Br J Haematol 1993 Oct; 85(2): 254–9
Piper MG, Massullo PR, Loveland M, et al. Neutrophil elastase down-modulates native G-CSFR expression and granulocyte-macrophage colony formation. J Inflamm (Lond) 2010; 7(1): 5
Tanaka H, Tokiwa T. Influence of renal and hepatic failure on the pharmacokinetics of recombinant human granulocyte colony-stimulating factor (KRN8601) in the rat. Cancer Res 1990 Oct 15; 50(20): 6615–9
Yang BB, Lum PK, Hayashi MM, et al. Polyethylene glycol modification of filgrastim results in decreased renal clearance of the protein in rats. J Pharm Sci 2004 May; 93(5): 1367–73
Emmanoual D, Lindheimer M, Katz A. Role of kidney in hormone metabolism and its implications in clinical medicine. Klin Wochenschr 1980; 58: 1005–12
Maack T, Johnson V, Kau ST, et al. Renal filtration, transport, and metabolism of low-molecular-weight proteins: a review. Kidney Int 1979 Sep; 16(3): 251–70
Nielson JT. Handling of proteins in isolated and in vitro perfused proximal tubules from rat kidney. Danish Med Bull 1990; 37: 197–210
Fukuda M, Oka M, Ishida Y, et al. Effects of renal function on pharmacokinetics of recombinant human granulocyte colony-stimulating factor in lung cancer patients. Antimicrob Agents Chemother 2001 Jul; 45(7): 1947–51
Kinstler O, Molineux G, Treuheit M, et al. Mono-N-terminal poly (ethylene glycol)-protein conjugates. Adv Drug Deliv Rev 2002 Jun 17; 54(4): 477–85
Molineux G. The design and development of pegfilgrastim (PEG-rmetHuG-CSF, Neulasta). Curr Pharm Des 2004; 10(11): 1235–44
Jain A, Jain SK. PEGylation: an approach for drug delivery. A review. Crit Rev Ther Drug Carrier Syst 2008; 25(5): 403–47
Jevsevar S, Kunstelj M, Porekar VG. PEGylation of therapeutic proteins. Biotechnol J 2010 Jan;5(1): 113–28
Harris JM, Martin NE, Modi M. Pegylation: a novel process for modifying pharmacokinetics. Clin Pharmacokinet 2001; 40(7): 539–51
Caliceti P, Veronese FM. Pharmacokinetic and biodistribution properties of poly (ethylene glycol)-protein conjugates. Adv Drug Deliv Rev 2003 Sep 26; 55(10): 1261–77
Fishburn CS. The pharmacology of PEGylation: balancing PD with PK to generate novel therapeutics. J Pharm Sci 2008 Oct;97(10): 4167–83
Tattini Jr V, Parra DF, Polakiewicz B, et al. Effect of lyophilization on the structure and phase changes of PEGylated-bovine serum albumin. Int J Pharm 2005 Nov 4; 304(1-2): 124–34
Tomiya N, Watanabe K, Awaya J, et al. Modification of acyl-plasmin-strep-tokinase complex with polyethylene glycol: reduction of sensitivity to neutralizing antibody. FEBS Lett 1985 Nov 25; 193(1): 44–8
Abuchowski A, Davis FF. Preparation and properties of polyethylene glycol-trypsin adducts. Biochim Biophys Acta 1979 May 23; 578(1): 41–6
Molineux G, Kinstler O, Briddell B, et al. A new form of filgrastim with sustained duration in vivo and enhanced ability to mobilize PBPC in both mice and humans. Exp Hematol 1999 Dec;27(12): 1724–34
Lord BI, Woolford LB, Molineux G. Kinetics of neutrophil production in normal and neutropenic animals during the response to filgrastim (r-metHu G-CSF) or filgrastim SD/01(PEG-r-metHu G-CSF). Clin Cancer Res 2001 Jul;7(7): 2085–90
Johnston E, Crawford J, Blackwell S, et al. Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy. J Clin Oncol 2000 Jul;18(13): 2522–8
Holmes FA, O’Shaughnessy JA, Vukelja S, et al. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol 2002 Feb 1; 20(3): 727–31
Green MD, Koelbl H, Baselga J, et al. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 2003 Jan;14(1): 29–35
Roskos LK, Lum P, Lockbaum P, et al. Pharmacokinetic/pharmacodynamic modeling of pegfilgrastim in healthy subjects. J Clin Pharmacol 2006 Jul;46(7): 747–57
Morstyn G, Campbell L, Souza LM, et al. Effect of granulocyte colony stimulating factor on neutropenia induced by cytotoxic chemotherapy. Lancet 1988 Mar 26; 1(8587): 667–72
Data on file, Amgen Inc., 2011
Yang BB. Integration of pharmacokinetics and pharmacodynamics into the drug development of pegfilgrastim, a pegylated protein. In: Meibohm B, editor. Pharmacokinetics and pharmacodynamics of biotech drugs. Weinheim: Wiley-VCH Verlag GmbH, 2006: 373–93
Holmes FA, Jones SE, O’Shaughnessy J, et al. Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer. Ann Oncol 2002 Jun;13(6): 903–9
Sierra J, Szer J, Kassis J, et al. A single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients treated for low-to-intermediate risk acute myeloid leukemia: results from a randomized, double-blind, phase 2 trial. BMC Cancer 2008; 8: 195
Kotto-Kome AC, Fox SE, Lu W, et al. Evidence that the granulocyte colony-stimulating factor (G-CSF) receptor plays a role in the pharmacokinetics of G-CSF and PegG-CSF using a G-CSF-R KO model. Pharmacol Res 2004 Jul;50(1): 55–8
Farese AM, Yang BB, Roskos L, et al. Pegfilgrastim, a sustained-duration form of filgrastim, significantly improves neutrophil recovery after auto-logous marrow transplantation in rhesus macaques. Bone Marrow Transplant 2003 Aug;32(4): 399–404
Wang B, Ludden TM, Cheung EN, et al. Population pharmacokinetic-pharmacodynamic modeling of filgrastim (r-metHuG-CSF) in healthy volunteers. J Pharmacokinet Pharmacodyn 2001 Aug;28(4): 321–42
Porter CJ, Charman SA. Lymphatic transport of proteins after subcutaneous administration. J Pharm Sci 2000 Mar;89(3): 297–310
Supersaxo A, Hein WR, Steffen H. Effect of molecular weight on the lymphatic absorption of water-soluble compounds following subcutaneous administration. Pharm Res 1990 Feb;7(2): 167–9
Lau D, Pilz D, Schwab G. Phase I pharmacokinetic and pharmacodynamic studies of G-CSF(filgrastim) in patients with renal or liver impairment compared to healthy volunteers [abstract]. Br J Haematol 1996; 93 Suppl. 2: 277
Yang BB, Kido A, Salfi M, et al. Pharmacokinetics and pharmacodynamics of pegfilgrastim in subjects with various degrees of renal function. J Clin Pharmacol 2008 Sep;48(9): 1025–31
Yang B-B, Savin MA, Green M. Prevention of chemotherapy-induced neutropenia with pegfilgrastim: pharmacokinetics and patient outcomes. Am J Hematol Oncol 2011; 10: 13–20
Mayani H. Human preleukemia: cellular, molecular and clinical aspects. Arch Med Res 1993; 24(4): 317–25
Yang BB, Lum P, Renwick J, et al. Pharmacokinetic rationale for a fixed-dose regimen of a sustained-duration form of filgrastim in cancer patients [abstract]. Blood 2000; 96 (11 Suppl. 1): 157b
George S, Yunus F, Case D, et al. Fixed-dose pegfilgrastim is safe and allows neutrophil recovery in patients with non-Hodgkin’s lymphoma. Leuk Lymphoma 2003 Oct;44(10): 1691–6
Neulasta®(pegfilgrastim): US prescribing information. Thousand Oaks (CA): Amgen Inc., 2010 [online]. Available from URL: http://pi.amgen.com/united_states/neulasta/neulasta_pi_hcp_english.pdf [Accessed 2011 Jan 19]
Aapro MS, Cameron DA, Pettengell R, et al. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 2006 Oct;42(15): 2433–53
Burstein HJ. Myeloid growth factor support for dose-dense adjuvant chemotherapy for breast cancer. Oncology (Williston Park) 2006 Dec; 20 (14 Suppl. 9): 13–5
Marangolo M, Bengala C, Conte PF, et al. Dose and outcome: the hurdle of neutropenia (review). Oncol Rep 2006 Aug;16(2): 233–48
Danova M, Bencardino K, Manzoni M, et al. In vivo biological effects of pegfilgrastim after myelosuppressive chemotherapy in breast cancer. Anti-cancer Res 2007 Sep-Oct; 27(5A): 3399–402
Invernizzi R, Grasso D, Travaglino E, et al. Biological effects of pegfilgrastim on circulating neutrophils in breast cancer patients undergoing dose-dense chemotherapy. Oncology 2008; 75(3-4): 237–44
Yang BB, Kido A, Shibata A. Serum pegfilgrastim concentrations during recovery of absolute neutrophil count in patients with cancer receiving pegfilgrastim after chemotherapy. Pharmacotherapy 2007 Oct;27(10): 1387–93
Pirker R, Ulsperger E, Messner J, et al. Achieving full-dose, on-schedule administration of ACE chemotherapy every 14 days for the treatment of patients with extensive small-cell lung cancer. Lung 2006 Sep-Oct; 184(5): 279–85
Lopez A, de Sevilla AF, Castaigne S, et al. Pegfilgrastim supports delivery of CHOP-R chemotherapy administered every 14 days: a randomised phase II study [abstract no. 3311]. Blood 2004; 104(11 Pt 1): 904–5a
Engert A, Bredenfeld H, Dohner H, et al. Pegfilgrastim support for full delivery of BEACOPP-14 chemotherapy for patients with high-risk Hodgkin’s lymphoma: results of a phase II study. Haematologica 2006 Apr;91(4): 546–9
Data on file, Amgen Inc., 2004–5
Acknowledgements
This work was supported by Amgen Inc. The authors wish to acknowledge the Amgen Pegfilgrastim Global Development Team. The authors thank Juan José Pérez Ruixo, PhD, Mi Rim Choi, MD, MBA, May Mo, MS, Holly Watson, MS, AOCN, and Lyndah Dreiling, MD, for reviewing the manuscript. Editorial assistance was provided by Julia R. Gage, PhD, on behalf of Amgen Inc. Both authors are employees and shareholders of Amgen Inc.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Yang, BB., Kido, A. Pharmacokinetics and Pharmacodynamics of Pegfilgrastim. Clin Pharmacokinet 50, 295–306 (2011). https://doi.org/10.2165/11586040-000000000-00000
Published:
Issue Date:
DOI: https://doi.org/10.2165/11586040-000000000-00000